Cargando…
Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity
Thyroid cancer is the most common endocrine neoplasm, and despite its overall high survival rate, patients with metastatic disease or tumors that resist radioactive iodine experience a significantly worse prognosis. Helping these patients requires a better understanding of how therapeutics alter cel...
Autores principales: | Bolf, Eric L., Beadnell, Thomas C., Rose, Madison M., D’Alessandro, Angelo, Nemkov, Travis, Hansen, Kirk C., Schweppe, Rebecca E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216321/ https://www.ncbi.nlm.nih.gov/pubmed/37408209 http://dx.doi.org/10.3390/cells12101374 |
Ejemplares similares
-
Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer
por: Mishall, Katie M., et al.
Publicado: (2017) -
Metabolic Signatures of Performance in Elite World Tour Professional Male Cyclists
por: Nemkov, Travis, et al.
Publicado: (2023) -
Deciphering Metabolic Adaptability of Leukemic Stem Cells
por: Patel, Sweta B., et al.
Publicado: (2022) -
Metabolomics of Endurance Capacity in World Tour Professional Cyclists
por: San-Millán, Iñigo, et al.
Publicado: (2020) -
Coordinate Regulation of Cholesterol and Bile Acid Metabolism by the Clock Modifier Nobiletin in Metabolically Challenged Old Mice
por: Nohara, Kazunari, et al.
Publicado: (2019)